Crystal Pharmatech Appoints New Vice President Of Scientific Development
Former Vice President at SSCI, Dr. Ann W. Newman, joins Crystal Pharmatech's leadership team as Vice President of Scientific Development and Head of the Scientific Advisory Board, effective February 1, 2012. This reflects another substantial action by Crystal Pharmatech Co., Ltd to expand its' executive team and talent base as the company steadily expands.
Ann is a senior pharmaceutical scientist with demonstrated scientific and leadership expertise in the pharmaceutical industry based on over 20 years of large pharma and contract research experience. Ann received her Ph.D. in Inorganic Chemistry from the University of Connecticut, Storrs. She has been a Principal Scientist at Bristol-Myers Squibb and an integral VP of Materials Science at SSCI. Ann has a wealth of knowledge in pharmaceutical sciences including solid state chemistry (polymorphs, salts, cocrystals, amorphous, dispersions), crystallization, and comprehensive physical characterization (active pharmaceutical ingredients (API), excipients, and drug products). Ann has authored over 40 technical publications, presented/collaborated on over 75 presentations, and presented over 55 webcasts.
Ann comes to Crystal Pharmatech with a perfect skill-set for their rapidly growing company. Ann played an integral role in the growth of SSCI (since purchased by Aptuit), including: staffing, systems design and implementation, client development, technical output, and scientific innovation. For those in the industry, SSCI was synonymous with solid state research outsourcing. Ann helped SSCI grow from tens of employees to a hundred employees, ensuring that talent was not diluted and growth areas were wisely evaluated.
"The addition of Ann to our executive team is important in many key areas" explains Alex Chen, CEO. "Ann brings a wealth of experience to Crystal Pharmatech both scientifically and in building a successful CRO company. Ann continues to be on the cutting-edge of solid-state research in API and drug product development. Her insights into problem solving and research will further enhance our scientific leadership team. The hiring of Ann reinforces our goal to be a global leader in solid state research in the Pharmaceutical industry."
"I really look forward to working with a group of great scientists and team members to grow Crystal Pharmatech into a premier research laboratory" says Ann Newman. "Working with consultants on the Scientific Advisory Board will also add another dimension to the ever-expanding research and project capabilities of the company".
Ann's role in Crystal Pharmatech will be quite diverse in scope. "Ann Newman is a perfect complement to the Crystal Pharmatech leadership team" explains Robert Wenslow, VP of Business Development. "With Ann's scientific prowess and business acumen, we are truly poised to become a global leader."
While at her role in Crystal Pharmatech, Ann will continue to maintain her consulting firm, Seventh Street Development Group, which provides consulting, training, and webcast services on solid-state pharmaceutics and pharmaceutical development
About Crystal Pharmatech
Crystal Pharmatech is a technology-driven CRO that focuses on the specialized field of solid state information for active pharmaceutical ingredients and formulations. It provides its clients a complete and satisfactory solution to the problem they face instead of merely running experiments and collecting data. For more information, visit www.crystalpharmatech.com.
SOURCE: Crystal Pharmatech Co., Ltd.